Grant: CIHR New Investigator
McGill University
$300,000.00
Mechanisms through which ShcA integrates tyrosine kinase signaling to promote breast cancer progression.
FY 2010-11
Summary
Breast cancer remains the most prevalent cancer in Canadian women and the second leading cause of cancer-related deaths in this group. While targeted therapies have contributed to a decreased incidence of breast cancer mortality, the prevalence of this disease dictates that novel biomarkers and/or therapeutic targets are required to further improve disease-free survival. The ShcA adaptor protein activates a critical signaling node in breast cancer cells to regulate diverse biological processes including tumor growth, survival and recruitment of a new blood supply, through a process termed angiogenesis. We have previously demonstrating that ShcA signaling in breast cancer cells regulates each of these processes to favor a pro-tumorigenic state, which facilitates breast cancer progression. We will mechanistically address how ShcA signaling favors a pro-tumorigenic and pro-angiogenic state using well characterized breast cancer mouse models. This will ultimately lead to the identification of novel, ShcA-regulated genes that functionally contribute to the tumorigenic process and which may represent viable targets for disease intervention.
Department
Program
CIHR New Investigator
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
213334
Name
Ursini-Siegel Giuseppina
Region
Québec
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
New Investigators A
Projecttitle
Mechanisms through which ShcA integrates tyrosine kinase signaling to promote breast cancer progression.
Programtype2
Salary Programs
Orgnameinp2
McGill University
Cihramount2
$300,000
Cihrequipment2
$0
Programname2
CIHR New Investigator
Keyworddelim
Breast Cancer; Erbb2; Receptor Tyrosine Kinase; Shca; Signal Transduction; Transgenic Mice; Tumor Angiogenesis; Tumor Immunity; Tumor Stroma
Abstract
Breast cancer remains the most prevalent cancer in Canadian women and the second leading cause of cancer-related deaths in this group. While targeted therapies have contributed to a decreased incidence of breast cancer mortality, the prevalence of this disease dictates that novel biomarkers and/or therapeutic targets are required to further improve disease-free survival. The ShcA adaptor protein activates a critical signaling node in breast cancer cells to regulate diverse biological processes including tumor growth, survival and recruitment of a new blood supply, through a process termed angiogenesis. We have previously demonstrating that ShcA signaling in breast cancer cells regulates each of these processes to favor a pro-tumorigenic state, which facilitates breast cancer progression. We will mechanistically address how ShcA signaling favors a pro-tumorigenic and pro-angiogenic state using well characterized breast cancer mouse models. This will ultimately lead to the identification of novel, ShcA-regulated genes that functionally contribute to the tumorigenic process and which may represent viable targets for disease intervention.
Competitiondate
201009
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Ursini-Siegel, Giuseppina
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $300,000~ $0~